Table 2 Demographic data, disease activity, cumulative clinical manifestations and treatments in childhood-onset systemic lupus erythematosus (cSLE) patients with autoimmune hepatitis (AIH) at diagnosis compared to those without AIH evaluated at last visit
Variables | cSLE with AIH (at AIH diagnosis) (n = 7) | cSLE without AIH (at last visit) (n = 28) | P |
|---|---|---|---|
Demographic data | |||
Age at diagnosis, years | 12.25 (10.3–15.6) | 12.9 (3.3–19.7) | 0.650 |
Disease duration, years | 0 (0–8.5) | 0.12 (0–8.5) | 0.060 |
Disease activity parameter | |||
SLEDAI-2 K | 6 (0–26) | 7 (0–41) | 0.755 |
Cumulative clinical manifestations | |||
Constitutional involvement | 6 (86) | 7 (25) | 0.006 |
Hepatomegaly | 5 (71) | 3 (11) | 0.003* |
Splenomegaly | 3 (43) | 1 (4) | 0.019 |
Musculoskeletal involvement | 4 (57) | 3 (11) | 0.018 |
Serositis | 0 (0) | 4 (7) | 1.000 |
Neuropsychiatric involvement | 0 (0) | 5 (18) | 0.559 |
Renal involvement | 2 (29) | 11 (39) | 0.689 |
Treatment | |||
Prednisone dose, mg/kg/day | 1.07 (0.5–2.4) | 0.9 (0.1–2.8) | 0.365 |
Antimalarial use | 3 (43) | 14 (50) | 1.000 |
Immunosuppressive use | 6 (86) | 8 (29) | 0.009 |